U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H7N.2Cl.Pt.H3N
Molecular Weight 376.147
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PICOPLATIN

SMILES

N.[Cl-].[Cl-].[Pt++].CC1=CC=CC=N1

InChI

InChIKey=IIMIOEBMYPRQGU-UHFFFAOYSA-L
InChI=1S/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;2*1H;1H3;/q;;;;+2/p-2

HIDE SMILES / InChI
Molecular Formula Pt
Molecular Weight 195.084
Charge 2
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C6H7N
Molecular Weight 93.1265
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
MOL RATIO 2 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula H3N
Molecular Weight 17.0305
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Picoplatin is a sterically hindered platinum (II) complex with antineoplastic properties developed for the treatment of cis-platin-resistant cancer. Picoplatin alkylates DNA, forming both inter- and intra-strand cross-linkages, resulting in inhibition of DNA replication and transcription, and the induction of apoptosis. However, in Phase III trials, picoplatin failed to meet its primary endpoint for advanced cell lung cancer. It remains in development for other cancers.

Originator

Johnson Matthey Technology and the Cancer Research Campaign
1

Approval Year

Unknown
139,594

Targets

Primary TargetPharmacologyConditionPotency
DNA
278
Crosslinking Agent
81
DNA topoisomerase I
59
Inhibitor
8,297

Conditions

ConditionModalityTargetsHighest PhaseProduct
Small-cell lung cancer
41
 Primary
Phase III
656
Unknown
Colorectal cancer
101
 Primary
Phase II
1,132
Unknown
Hormone refractory prostate cancer
5
 Primary
Phase II
1,132
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
7530 μg/mL
120 mg/m² 1 times / 3 weeks steady-state, intravenous
 PICOPLATIN plasma
Homo sapiens
3250 μg/L
120 mg/m² 1 times / 3 weeks steady-state, intravenous
 PICOPLATIN plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
12000 μg × h/L
120 mg/m² 1 times / 3 weeks steady-state, intravenous
 PICOPLATIN plasma
Homo sapiens
13078 μg × h/L
120 mg/m² 1 times / 3 weeks steady-state, intravenous
 PICOPLATIN plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
0.83 h
120 mg/m² 1 times / 3 weeks steady-state, intravenous
 PICOPLATIN plasma
Homo sapiens
85.7 h
120 mg/m² 1 times / 3 weeks steady-state, intravenous
 PICOPLATIN plasma
Homo sapiens

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
OCT1
327

OCT3
80

OCT2
355

MRP1
107

Drug as victim

PubMed

Patents

0123121
1
8168661
1
8168662
1
8173686
1
8178564
1

Sample Use Guides

In Vivo Use Guide
In a clinical trial, picoplatin was administered intravenously at a dose of 150 mg/m2 every 3 weeks.
Route of Administration: Intravenous
In Vitro Use Guide
In a growth inhibition assay, ovarian carcinoma cell lines were treated serial dilutions of picoplatin for 96 h. Among the cell lines, the drug demonstrated a mean IC50 value of 8.1 uM.
Substance Class Chemical
Record UNII
B5TAN0L720
Record Status Validated (UNII)
Record Version
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966